Haddon Heights
Haddon Heights
Haddon Heights, New Jersey, United States16 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3 | Arrhythmias, Cardiac, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrial fibrillation, cardiovascular disorder, heart disorder | Recruiting | Phase 3 | 2026-10-07 | NCT06716021 | |
| Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention | Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, hyperlipidemia, metabolic disease, myocardial ischemia, vascular disorder | Recruiting | Phase 4 | 2026-10-05 | NCT06909565 | |
| A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | Arrhythmias, Cardiac, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrial fibrillation, cardiovascular disorder, heart disorder | Active, not recruiting | Phase 3 | 2026-09-25 | NCT05757869 | |
| Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias | Arrhythmias, Cardiac, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrial fibrillation, cardiovascular disorder, heart disorder, paroxysmal atrial fibrillation, persistent atrial fibrillation | Recruiting | Not stated | 2026-09-22 | NCT04088071 | |
| ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | Acute Myocardial Infarction (AMI); Cardiovascular Risk | Active, not recruiting | Phase 3 | 2026-09-09 | NCT06118281 | |
| A Registry Based Collaborative to Measure Efficiency, Effectiveness, and Safety of Farapulse PFA Technology for AF | Arrhythmias, Cardiac, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrial fibrillation, cardiovascular disorder, heart disorder | Enrolling by invitation | Not stated | 2026-08-27 | NCT06335082 | |
| Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, hyperlipidemia, metabolic disease, vascular disorder | Active, not recruiting | Phase 3 | 2026-08-25 | NCT05030428 | |
| A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, vascular disorder | Recruiting | Phase 3 | 2026-08-24 | NCT07000357 | |
| A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, cardiovascular disorder, heart disorder, heart failure, nutritional disorder, obesity disorder, overnutrition | Recruiting | Phase 3 | 2026-08-18 | NCT07567001 | |
| Assessment of CCM in HF With Higher Ejection Fraction | cardiovascular disorder, diastolic heart failure, heart disorder, heart failure | Recruiting | Not applicable | 2026-08-06 | NCT05064709 | |
| VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease | Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, hyperlipidemia, metabolic disease, vascular disorder | Active, not recruiting | Phase 4 | 2026-07-29 | NCT06249165 | |
| Assessment of Combined CCM and ICD Device in HFrEF | Arrhythmias, Cardiac, Cardiac Conduction System Disease, Death, Death, Sudden, Death, Sudden, Cardiac, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Tachycardia, cardiac arrest, cardiovascular disorder, heart disorder, heart failure, sudden cardiac arrest, ventricular fibrillation, ventricular tachycardia | Active, not recruiting | Not applicable | 2026-05-27 | NCT05855135 | |
| SyncAV Post-Market Trial | cardiovascular disorder, congestive heart failure, heart disorder, heart failure | Active, not recruiting | Not applicable | 2025-12-18 | NCT04100148 | |
| Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy | cardiovascular disorder, heart disorder, heart failure | Active, not recruiting | Not stated | 2025-11-20 | NCT03970343 | |
| Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Recruiting | Phase 3 | 2024-10-22 | NCT02901184 | |
| RADIANCE Continued Access Protocol | Hypertension Resistant to Conventional Therapy, cardiovascular disorder, essential hypertension, hypertensive disorder, vascular disorder | Active, not recruiting | Not applicable | 2024-06-17 | NCT05017935 |